Thromboembolism in pregnancy: Recurrence risks, prevention and management

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 6, 2008, Pages 550-556

  James, Andra H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Arterial thromboembolism; Deep vein thrombosis; Pregnancy; Pulmonary embolus; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; ESTROGEN; GESTAGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; BONE DENSITY; CESAREAN SECTION; CHILDBIRTH; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG MONITORING; FIRST TRIMESTER PREGNANCY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; LOW DRUG DOSE; LUNG EMBOLISM; MATERNAL MORTALITY; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; POSTOPERATIVE CARE; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROPHYLAXIS; PUERPERIUM; RADIODIAGNOSIS; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

ANTICOAGULANTS; CESAREAN SECTION; FEMALE; HUMANS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; RECURRENCE; RISK; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 56849095810     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e328317a427     Document Type: Review

References (77)

1. James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005; 106:509-516.
2. James AH, Jamison MG, Biswas MS, et al. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 2006; 113:1564-1571.
3. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697-706.
4. Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. N Engl J Med 1996; 335:768-774.
5. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194:1311-1315.
6. Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999; 94 (5 Pt 1):730-734.
7. Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001; 108:56-60.
8. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol 2005; 193:216-219.
9. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999; 54:265-271.
10. Ulander VM, Lehtola A, Kaaja R. Long-term outcome of deep venous thrombosis during pregnancy treated with unfractionated heparin or low molecular weight heparin. Thrombosis Res 2003; 111:239-242.
11. Kierkegaard A. Side and site of deep vein thrombosis in women using oral contraceptives. Acta Obstet Gynecol Scand 1985; 64:399-402.
12. Kierkegaard A. Deep vein thrombosis and the oestrogen content in oral contraceptives. An epidemiological analysis. Contraception 1985; 31:29-41.
13. Cockett FB, Thomas ML. The iliac compression syndrome. Br J Surg 1965; 52:816-821.
14. Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67:519-520.
15. Goldhaber SZ, Tapson VF. A prospective registry of 5451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93:259-262.
16. Gordon, M. Maternal physiology in pregnancy. In: Gabbe S, Niebyl J, Simpson J, editors. Normal and problem pregnancies. NYC: Churchill Livingstone; 2002. pp. 63-92.
17. Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 1997; 104:191-197.
18. Whitty J, Dombrowski M. Respiratory diseases in pregnancy. In: Gabbe S, Niebyl J, Simpson J, editors. Normal and problem pregnancies. NYC: Churchill Livingstone; 2002. pp. 1033-1064.
19. Danilenko-Dixon DR, Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001; 184:104-110.
20. Carr MH, Towers CV, Eastenson AR, et al. Prolonged bed rest during pregnancy: does the risk of deep vein thrombosis warrant the use of routine heparin prophylaxis? J Matern Fetal Med 1997; 6:264-267.
21. Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol 2000; 182:1089-1092.
22. Sikovanyecz J, Orvos H, Pal A, et al. Leiden mutation, bed rest and infection: simultaneous triggers for maternal deep-vein thrombosis and neonatal intracranial hemorrhage? Fetal Diagn Ther 2004; 19:275-277.
23. Postpartum hemorrhage: prevention of postpartum hemorrhage initiative. Office of Health, Infectious Diseases and Nutrition, Bureau for Global Health [Website] 2007 [cited January 28, 2007]. [Available from: http://www. pphprevention.org/pph.php].
24. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance: United States, 1991-1999. MMWR Surveill Summ 2003; 52:1-8.
25. Pabinger I, Grafenhofer H, Kyrle PA, et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100:1060-1062.
26. Lamy C, Hamon JB, Coste J, Mas JL. Ischemic stroke in young women: risk of recurrence during subsequent pregnancies. French Study Group on Stroke in Pregnancy. Neurology 2000; 55:269-274.
27. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343:1439-1444.
28. Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3:949-954.
29. De Stefano V, Martinelli I, Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006; 135:386-391.
30. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668-672.
31. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001; 108:1134-1140.
32. Dilley A, Austin H, El-Jamil M, et al. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obstet Gynecol 2000; 183:1271-1277.
33. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374-380.
34. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132:171-196.
35. Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med 1989; 149:2233-2236.
36. Greer IA, Nelson-Piercy C. Low-molecular-weight heparine for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401-407.
37. James AH, Brancazio LR, Gehrig TR, et al. Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med 2006; 19:643-549.
38. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed.). Chest 2006; 133 (6 Suppl):844S-886S. This article is actually a chapter in the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). This chapter thoroughly and comprehensively reviews the evidence for the use of anticoagulation to prevent and treat venous thromboembolism in pregnancy. These guidelines, revised and updated, were just published in June 2008. They are considered to be the definitive resource by experts in the field.
39. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003; 101:1333-1344.
40. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103:3695-3699.
41. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340:9-13.
42. James A, Brancazio L, Ortel T. Thrombophilia in pregnancy: maternal and fetal implications. Curr Womens Health Rev 2006; 2:51-59.
43. Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995; 173:1240-1245.
44. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181 (5 Pt 1):1113-1117.
45. Norris LA, Bonnar J, Smith MP, et al. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb Haemost 2004; 92:791-796.
46. Smith MP, Norris LA, Steer PJ, et al. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190:495-501.
47. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191:1024-1029.
48. Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul Fibrinolysis 1998; 9:343-350.
49. Flessa HC, Kapstrom AB, Glueck HI, Will JJ. Placental transport of heparin. Am J Obstet Gynecol 1965; 93:570-573.
50. Harenberg J, Schneider D, Heilmann L, Wolf H. Lack of antifactor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 1993; 23:314-320.
51. Schneider D, Heilmann L, Harenberg J. Placental transfer of low-molecular weight heparin. Geburtshilfe Frauenheilkd 1995; 55:93-98.
52. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994; 170 (5 Pt 1):1315-1320.
53. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170:862-869.
54. Casele H, Haney EI, James A, et al. Bone density changes in women who receive thromboprophylaxis in pregnancy. Am J Obstet Gynecol 2006; 195:1109-1113.
55. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265-1270.
56. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001; 185:148-152.
57. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl):627S-644S.
58. Pettila V, Leinonen P, Markkola A, et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87:182-186.
59. Carlin AJ, Farquharson RG, Quenby SM, et al. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod 2004; 19:1211-1214.
60. Casele H, Haney E. Bruising in women undergoing thromboprophylaxis in pregnancy. Am J Obstet Gynecol 2006; 193:S81.
61. James AH, Brancazio LR, Ortel TL. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol 2005; 3:187-197.
62. ACOG, Thromboembolism in pregnancy. American College of Obstetrician and Gynecologists; 2000. p. 1-9.
63. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002; 99:333-341.
64. Coppage KH, Hinton AC, Moldenhauer J, et al. Maternal and perinatal outcome in women with a history of stroke. Am J Obstet Gynecol 2004; 190:1331-1334.
65. James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv 2008; 63:49-57.
66. Stewart JA, Hamilton PJ, Murdoch AP. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 1997; 12:2167-2173.
67. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
68. Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002; 100:3470-3478.
69. Schafer AI, Levin MN, Konkle BA, Kearon C. Thrombotic disorders: diagnosis and treatment. Hematology (Am Soc Hematol Educ Program) 2003:520-539.
70. Horlocker TT. Low molecular weight heparin and neuraxial anesthesia. Thromb Res 2001; 101:141-154.
71. Baker WH, Mahler DK, Foldes MS, et al. Pneumatic compression devices for prophylaxis of deep venous thrombosis (DVT). Am Surg 1986; 52:371-373.
72. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J 1996; 41:83-86.
73. Jacobson AF, Drolsum A, Klow NE, et al. Deep vein thrombosis after elective cesarean section. Thromb Res 2004; 113:283-288.
74. Orme ML, Lewis PJ, de Swiet M, et al. May mothers given warfarin breast-feed their infants? Br Med J 1977; 1:1564-1565.
75. McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? J Pediatr 1983; 103:325-327.
76. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776-789.
77. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315-324.